Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population: A 52-week prospective study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Suh, G.-H. | - |
dc.contributor.author | Hee, Y.J. | - |
dc.contributor.author | Chang, U.L. | - |
dc.contributor.author | Choi, S. | - |
dc.contributor.author | Sang, K.L. | - |
dc.contributor.author | Ju, Y.-S. | - |
dc.contributor.author | Byeong, K.Y. | - |
dc.contributor.author | Lee, N.-J. | - |
dc.contributor.author | Jae, H.K. | - |
dc.contributor.author | Baik, S.K. | - |
dc.contributor.author | Dae, G.K. | - |
dc.contributor.author | Kim, Y.-H. | - |
dc.contributor.author | Jung, H.L. | - |
dc.contributor.author | Hong, I. | - |
dc.contributor.author | Byoung, H.O. | - |
dc.contributor.author | Jae, N.B. | - |
dc.contributor.author | Jung, H.-Y. | - |
dc.contributor.author | Park, J.-H. | - |
dc.date.accessioned | 2021-06-18T13:41:40Z | - |
dc.date.available | 2021-06-18T13:41:40Z | - |
dc.date.issued | 2008-02 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.issn | 1598-6357 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/46975 | - |
dc.description.abstract | To evaluate the impact of galantamine treatment on the function, caregiver time, and resource used in the treatment of patients with mild to moderate Alzheimer's disease (AD), costs and outcomes were evaluated during a 52-week prospective, randomized, double-blind, community-controlled trial of galantamine. Patients received either galantamine treatment (n=72) or no treatment (n=66). The analysis was performed from a societal perspective. Galantamine treatment reduced time spent caring for the patients and maintained improved functional capacity, whereas, when no treatments were given, a great increase in caregiver time and progressive functional deteriorations were observed. Saved caregiver time was equivalent to 113 working days per year. After 52 weeks, mean total annual costs per patient were 14,735,000 Korea Won (KRW) (USD 12,315) for patients with galantamine treatment and 25,325,000 KRW (USD 21,166) for patients without treatment. Adjusted annual cost saving of galantamine treatment was 6,428,000 KRW (USD 5,372) when compared to no treatment (p=0.0089). Galantamine had a beneficial effect not only to slow functional decline in patients with mild to moderate AD, but also to save a substantial amount of costs, closely related to reduction in caregiver burden and decrease in caregiver time. Copyright © The Korean Academy of Medical Sciences. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.title | Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population: A 52-week prospective study | - |
dc.type | Article | - |
dc.identifier.doi | 10.3346/jkms.2008.23.1.10 | - |
dc.identifier.bibliographicCitation | Journal of Korean Medical Science, v.23, no.1, pp 10 - 17 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-40549134510 | - |
dc.citation.endPage | 17 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 10 | - |
dc.citation.title | Journal of Korean Medical Science | - |
dc.citation.volume | 23 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Alzheimer disease | - |
dc.subject.keywordAuthor | Benefit | - |
dc.subject.keywordAuthor | Caregivers | - |
dc.subject.keywordAuthor | Double blind method | - |
dc.subject.keywordAuthor | Economy | - |
dc.subject.keywordAuthor | Function | - |
dc.subject.keywordAuthor | Galantamine | - |
dc.subject.keywordAuthor | Randomized controlled trial | - |
dc.subject.keywordAuthor | RCT | - |
dc.subject.keywordAuthor | Trial | - |
dc.subject.keywordPlus | cholinesterase inhibitor | - |
dc.subject.keywordPlus | galantamine | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | Alzheimer disease | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | clinical trial | - |
dc.subject.keywordPlus | controlled clinical trial | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | cost of illness | - |
dc.subject.keywordPlus | double blind procedure | - |
dc.subject.keywordPlus | economics | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | health care cost | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | prospective study | - |
dc.subject.keywordPlus | randomized controlled trial | - |
dc.subject.keywordPlus | Aged | - |
dc.subject.keywordPlus | Alzheimer Disease | - |
dc.subject.keywordPlus | Cholinesterase Inhibitors | - |
dc.subject.keywordPlus | Cost of Illness | - |
dc.subject.keywordPlus | Double-Blind Method | - |
dc.subject.keywordPlus | Female | - |
dc.subject.keywordPlus | Galantamine | - |
dc.subject.keywordPlus | Health Care Costs | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Male | - |
dc.subject.keywordPlus | Prospective Studies | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.